ATAI Life Sciences

Atai Life Sciences (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on mental health innovation, announced its third-quarter 2024 financial results Wednesday as well as updates on its clinical and corporate strategies. With notable advancements in its investigational programs, the...

Psychedelics have shown promise in treating various mental health issues, including PTSD and depression, but they’ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for "bad trips" have raised concerns among both clinicians and patients. As...

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) in which it calls for an additional phase 3 trial to further evaluate its safety and efficacy. As Psychiatric Times...

The global psychedelic drugs market is poised for significant growth over the next five years, with an estimated increase of USD 1.37 billion from 2024 to 2028, according to a report by Technavio. The market is projected to grow at a compound annual growth rate (CAGR) of 11.82%, fueled by the...

Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-...

Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).  The randomized, double-blind, placebo-controlled, single-...

Atai Life Sciences N.V. (NASDAQ: ATAI) recently filed a registration statement with the Securities and Exchange Commission for capital raise of up to $300 million through the issuance of common shares, debt securities, warrants and units. As explained by Jason Najum on Microdose, by using a...

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Glenn Short, PhD, Vice President of Early Development, at ATAI Life Sciences (NASDAQ: ATAI) was a guest speaker at Benzinga’s Psychedelic Capital...

atai Life Sciences N.V. (NASDAQ: ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included:  Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly...

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.   Collaboration with the National Institute...

Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent investors who are backing research into psychedelic ventures. Last week, Jurvetson spoke at the New York City conference “Horizons: Perspectives on Psychedelics” on the...

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pathways (NASDAQ: CMPS), a drug developer looking to accelerate patient access to psilocybin...

Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug industry.  Psychedelic drugs, such as psilocybin mushrooms and LSD, were once seen merely as a way for college...

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after submitting an application to uplist its shares from Toronto’s NEO exchange, MindMed (OTCQB: MMEDF) confirmed it will commence trading on the Nasdaq Capital...

Co-written by Andrew Ward and Natan Ponieman The race is continually heating up in the psychedelics space. An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment. The race has...